FORMER NFL PLAYER CONVICTED IN $328 MILLION MEDICARE GENETIC TESTING FRAUD SCHEME

A federal jury in Dallas has convicted Texas laboratory owner and former NFL player Keith J. Gray, 39, of McKinney, Texas, for orchestrating a massive $328 million cardiovascular genetic testing fraud scheme that targeted Medicare through kickbacks, telemarketing exploitation, and falsified medical necessity claims.

Trial evidence established that Gray owned and operated two clinical laboratories — Axis Professional Labs LLC (Axis) and Kingdom Health Laboratory LLC (Kingdom) — which billed Medicare for large volumes of genetic tests designed to assess cardiovascular disease risk. Prosecutors demonstrated that the tests were medically unnecessary and driven by profit incentives rather than patient care.

The scheme operated through a structured referral pipeline.

Gray paid illegal kickbacks to marketing intermediaries in exchange for Medicare beneficiary DNA samples, personal identifying information, Medicare numbers, and pre-signed physician test orders. The marketers, in turn, contracted telemarketing companies that cold-called Medicare beneficiaries nationwide. Non-medical personnel “qualified” patients over the phone, gathering health details and personal data without physician involvement.

A process known as “doctor chase” followed. Telemarketing entities identified beneficiaries’ primary care physicians and pressured them to sign off on genetic testing orders for patients who had already been processed through sales funnels. Physicians were presented with testing requests tied to patients they often had not evaluated for cardiovascular genetic risk in the relevant context.

The structure effectively inverted medical judgment — diagnostic orders were generated downstream of telemarketing activity rather than upstream from clinical necessity.

To conceal kickback payments, Gray used sham contracts and fabricated invoices. Payments were disguised as compensation for “marketing hours,” though trial evidence showed these invoices were reverse-engineered to match agreed per-sample kickback rates. Additional concealment mechanisms included labeling payments as “software” fees or documenting them as loans that did not exist.

Text message evidence presented at trial reflected the scale of illicit proceeds. In one exchange, Gray’s co-conspirator wrote, “$ent, you should have it any minute if you don’t already. Get it?” Gray responded, “Sorry I was filling my bathtub with ones. Yes lol.” The communication was introduced to demonstrate knowledge, intent, and profit motive tied to Medicare reimbursement flows.

Between Axis and Kingdom, the laboratories submitted approximately $328 million in claims to Medicare. Federal payment records showed that Medicare disbursed approximately $54 million before the scheme was disrupted.

Prosecutors also established that Gray laundered portions of the fraud proceeds through luxury asset acquisitions. Purchases included a Dodge Ram truck valued at more than $142,000 and a Mercedes-Benz SUV valued at more than $145,000. These transactions formed part of the money laundering counts, illustrating conversion of federal program funds into personal high-value assets.

The jury convicted Gray on the following counts:

• Conspiracy to defraud the United States and to pay and receive health care kickbacks
• Five counts of violating the Anti-Kickback Statute
• Three counts of money laundering

Each count carries a statutory maximum penalty of 10 years in federal prison. Sentencing will be determined by a federal district court judge after consideration of the U.S. Sentencing Guidelines and statutory factors.

The investigation involved federal and state enforcement agencies with jurisdiction over financial crimes, Medicare fraud, Medicaid oversight, and veteran health care protections. The prosecution was handled by trial attorneys within the Criminal Division’s Fraud Section.

The case reflects a recurring enforcement focus within federal health care fraud initiatives targeting diagnostic testing schemes that exploit genetic medicine billing codes. Cardiovascular genetic testing has emerged as a high-risk fraud category in recent years due to reimbursement rates and the ability to scale claims through centralized laboratory processing.

The broader enforcement program has charged thousands of defendants nationwide since 2007 in health care fraud cases involving billions of dollars in alleged fraudulent billings across federal programs and private insurers. The conviction reinforces ongoing federal scrutiny of laboratory billing practices, telemedicine referral networks, and kickback-driven diagnostic pipelines.

This prosecution underscores a structural vulnerability within Medicare: when laboratory ownership, marketing networks, and physician authorization channels converge without independent clinical safeguards, reimbursement systems can be converted into automated revenue streams detached from patient need.

The Dallas jury’s verdict signals continued aggressive prosecution of high-dollar genetic testing fraud and kickback conspiracies operating under the veneer of medical innovation.

---

---

---

---

---

---

---

---

🔥 NOW AVAILABLE! 🔥

‎👉 Eclipsera – Apple Music

---

---

---

---

---